KRAS and intrahepatic cholangiocarcinoma: Investigators had sequenced tumors and matching control sample pairs of a large cohort of 103 intrahepatic cholangiocarcinoma patients in China, disclosing 25 significantly mutated genes including eight potential driver genes, gene TP53, KRAS, IDH1, PTEN, ARID1A, EPPK1, ECE2 and FYN [22].